Community Series in Exploring Immunological Tolerance in Allergy Treatment through AIT Volume II

This Research Topic is the second volume of the “Exploring Immunological Tolerance in Allergy Treatment through AIT” Community Series. Please see Volume I hereImmunoglobulin E (IgE)-mediated allergic reactions pose significant challenges, despite the advent of Allergen-Specific Immunotherapy (AIT), the sole treatment modifying allergic patient responses to natural allergen exposure. AIT employs repetitive, route-specific allergen administration, evolving from subcutaneous and sublingual methods to recent oral immunotherapy and potential intralymphatic and epicutaneous avenues. This therapy modifies immune responses by suppressing allergic effector cells like mast cells and basophils, fostering a shift from Th2 to Th1 responses, and promoting regulatory T and B cells with suppressive abilities. Despite its established usage, AIT's full mechanistic impact remains underexplored, particularly concerning the roles and modifications of effector cells, antibody interactions, and cellular epitopes.This Research Topic aims to elucidate the molecular and cellular mechanisms that underlie the clinical success of allergen immunotherapy (AIT) in inducing long-term immunological tolerance. By examining the immunological basis of AIT—including alterations in T and B cell function, cytokine profiles, and antibody responses—this collection seeks to bridge the gap between observed clinical efficacy and the underlying biological processes. A deeper understanding of these mechanisms will support the optimization and personalization of AIT strategies, ultimately enhancing therapeutic outcomes.To gather further insights within this dynamic field, we welcome articles addressing, but not limited to, the following themes:T and B cell changes and mechanisms during AITSuppression mechanisms of specific effector cells in AITRoles of antigen-presenting and innate lymphoid cellsDevelopment and refinement of in vitro and in vivo models for AITInnovations in the use of recombinant allergens and antibodiesTopic Editor, Jamie M Orengo is an employee and shareholder of Regeneron Pharmaceuticals. Caterina Vizzardelli declares no competing interests with regard to this Research Topic. Topic editors: Caterina Vizzardelli, Jamie Marie Orengo Source: https://www.frontiersin.org/research-topics/72488/community-series-in-exploring-immunological-tolerance-in-allergy-treatment-through-ait-volume-ii